European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023 - Biomarqueurs et Essais Cliniques en Cancérologie et Onco-Hématologie Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2023

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

1 NKUA - National and Kapodistrian University of Athens
2 Eberhard Karls Universität Tübingen = University of Tübingen
3 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
4 The University of Sydney
5 Royal Prince Alfred Hospital [Sydney, Australia]
6 Melanoma Institute Australia [Sydney, NSW, Australia]
7 MV2C - Mount Vernon Cancer Centre [Northwood, UK]
8 OUH - Odense University Hospital
9 INCIT - Immunology and New Concepts in ImmunoTherapy
10 University hospital of Zurich [Zurich]
11 UNIVAQ - University of L'Aquila [Italy]
12 UniBuc - University of Bucharest
13 Barts and the London Medical School
14 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
15 Medizinische Universität Wien = Medical University of Vienna
16 2MA - Military Medical Academy [Belgrade, Serbia]
17 Frankfurt University Hospital
18 MUMC - Maastricht University Medical Centre
19 Aristotle University of Thessaloniki
20 University of Barcelona
21 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
22 CIBER de Enfermedades Raras (CIBERER)
23 ULB - Hôpital Erasme [Bruxelles]
24 Hospital Universitario Virgen Macarena [Séville]
25 UNIROMA - Università degli Studi di Roma "La Sapienza" = Sapienza University [Rome]
26 FPUAG - Fondazione Policlinico Universitario A. Gemelli [Rome]
27 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
28 Hôpital Ambroise Paré [AP-HP]
29 BECCOH - Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
30 Universidade de Coimbra [Coimbra]
31 Università degli studi di Trieste = University of Trieste
32 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
33 UMCU - University Medical Center [Utrecht]
34 AMU - Aix Marseille Université
35 University of Manchester [Manchester]
Lars Bastholt
Ana Maria Forsea
Aimilios Lallas

Résumé

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.
Fichier principal
Vignette du fichier
PIIS0959804923003532.pdf (1.79 Mo) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

inserm-04210036 , version 1 (18-09-2023)

Licence

Identifiants

Citer

Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More